Figure 3

Effects of NTs and the inhibitors of Trk (K252a), TrkB (ANA-12) and p75^NTR(anti-p75) on TASMC proliferation in GCA patients and controls. Proliferation assay performed with a BrdU assay on day 1 (A) in serum-starved TASMC incubated with NT or NT receptor inhibitors, or a combination of NT and NT receptor inhibitors, in GCA patients (n = 6) and controls (n = 10). In all figures, bars represent the mean of three experiments with their SEMs. K252a: specific Trk receptor inhibitor; ANA-12: a specific TrkB receptor inhibitor; anti-p75: p75^NTR Ab inhibitor; N (NGF) or B (BDNF) + K (K252a) or anti-p75^NTR: NGF or BDNF are added at the same time with the specific inhibitor. (B) Effect of ANA-12 on GCA-derived TASMCs proliferation. Three independent assays were performed and cells were seeded in triplicate for each cell line. BDNF, brain-derived neurotrophic factor; GCA, giant-cell arteritis; NGF, nerve growth factor; NT, neurotrophin; SEM, standard errors of the mean; TASMC, temporal artery VSMC; Trk, tropomyosin receptor kinase; VSMC, vascular smooth muscle cell.